• Molecular NameTelbivudine
  • Synonym2'-Deoxy-L-thymidine; Beta-l-thymidine; Epavudine; L-deoxythymidine; L-DT; L-thymidine; LDT; Telbivudin; telbivudine
  • Weight242.231
  • Drugbank_IDDB01265
  • ACS_NO3424-98-4
  • Show 2D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)-1.36
  • pkaN/A
  • LogD (pH=7, predicted)-1.36
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-1.62
  • LogSw (predicted, AB/LogsW2.0)16.55
  • Sw (mg/ml) (predicted, ACD/Labs)5.79
  • No.of HBond Donors3
  • No.of HBond Acceptors7
  • No.of Rotatable Bonds2
  • TPSA99.1
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyAn antiviral drug used in the treatment of hepatitis B infection.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability68.0
  • Protein binding3.3
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmNo metabolites of telbivudine were detected following administration of [14C]??????telbivudine in humans. Telbivudine is not a substrate, or inhibitor of the cytochrome P450 (CYP450) enzyme system.
  • Half life15 h
  • ExcretionRenal
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityThere is no information on intentional overdose of telbivudine, but one subject experienced an unintentional and asymptomatic overdose. Healthy subjects who received telbivudine doses up to 1800 mg/day for 4 days had no increase in or unexpected adverse events. A maximum tolerated dose for telbivudine has not been determined.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A